Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.32 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | BHMT | Q93088 | 1/20 | 0.30 |
| ▸ | CPB1 | P15086 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17072565 | 0.83 | TSHR (0.37) | ECE1CACNA2D1CACNB3CACNA1CPGR | |
| SCHEMBL17030034 | 0.83 | GABRP (0.41) | ECE1 | |
| SCHEMBL17072563 | 0.78 | EPHX1 (0.31) | CYP2C19 | |
| SCHEMBL17030200 | 0.77 | NOS3 (0.30) | — | |
| SCHEMBL17030211 | 0.76 | BHMT (0.38) | ECE1CACNA2D1CACNB3CACNA1CPGR | |
| SCHEMBL17030205 | 0.75 | NOS3 (0.30) | — | |
| SCHEMBL17030106 | 0.74 | ROCK2 (0.31) | — | |
| SCHEMBL17029968 | 0.72 | — | — | |
| SCHEMBL17030185 | 0.72 | BHMT (0.36) | ECE1CACNA2D1CACNB3CACNA1CPGR | |
| SCHEMBL17029989 | 0.71 | ITGB3 (0.34) | CACNA2D1CACNB3CACNA1CPGRADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150250217-A1 | SALTY TASTE-ENHANCING AGENT AND MANUFACTURING METHOD THEREFOR, AND SALTY TASTE-ENHANCING METHOD | NISSAN FOODS HOLDINGS CO., LTD. (JP) | 2015-09-10 | — | — | US | disclosed |
| EP-2910130-A1 | SALTY TASTE-ENHANCING AGENT AND MANUFACTURING METHOD THEREFOR, AND SALTY TASTE-ENHANCING METHOD | Nissin Foods Holdings Co., Ltd. (JP) | 2015-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150250217-A1 | SALTY TASTE-ENHANCING AGENT AND MANUFACTURING METHOD THEREFOR, AND SALTY TASTE-ENHANCING METHOD | TAS2R8, TAS2R13, TAS2R38 | ECE1 3367/4885CACNA2D1 2861/4885CACNB3 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.